Alumis Inc. has announced the successful completion of patient enrollment in its pivotal Phase 3 ONWARD clinical program for ESK-001, a treatment for moderate-to-severe plaque psoriasis, involving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback